The strong institutional accumulation, especially by major holders like Jennison Associates, signals conviction in the NDA submission catalyst. Monitor for completion of the rolling NDA submission in H2 2026 and any regulatory updates. The $250.6M cash runway through 2027 reduces near-term dilution risk. The lack of insider buying (confluence score 22/100, divergent) tempers the signal slightly but does not negate the institutional vote of confidence.
Executive Summary
13 institutional buyers accumulated $83.1M in PVLA during Q2 2026, led by Jennison Associates adding $66.9M (50% increase), while only one seller trimmed $1.04M. This strong accumulation follows the company's Q2 earnings miss (mechanical EPS miss for pre-revenue biotech) and aligns with the ongoing rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, on track for completion in H2 2026.
Key Financial Metrics
Institutional Positions
Net institutional flow: $82.1M
▲ Buyers (13)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Jennison Associates | ADD | +50% | $146.8M | $66.9M |
| Aberdeen Group | ADD | +48.3% | $18.4M | $8.3M |
| Bank Of New York Mellon | ADD | +69.5% | $4.7M | $2.4M |
| Citigroup | DOUBLED | +518.7% | $2.4M | $2.1M |
| Russell Investments Group | ADD | +65.2% | $3.4M | $1.7M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| New York State Common Retirement Fund | TRIM | -50.7% | $2.6M | -$1.0M |
Key Facts
- 13 institutional buyers vs 1 seller in Q2 2026
- Net institutional inflow of $83.1M, with total buyer holdings of $179.4M
- Jennison Associates added $66.9M (50% increase to $146.8M)
- Aberdeen Group added $8.3M (48.3% increase to $18.4M)
- Only seller: New York State Common Retirement Fund trimmed $1.04M (50.7% reduction)
- Q2 2026 EPS miss of -$1.52 vs consensus -$1.15 (32% miss) was a mechanical artifact of increased R&D and dilution, not business deterioration
- Cash position of $250.6M funds operations and launch preparations through 2027
- NDA submission for QTORIN rapamycin on track for H2 2026, potential U.S. launch H1 2027
Financial Impact
Net institutional accumulation of $83.1M in Q2 2026, with 13 buyers adding $83.1M and 1 seller reducing by $1.04M
Risk Factors
- Clinical and regulatory risk: NDA submission may face delays or rejection
- Pre-revenue stage: no approved products, reliance on pipeline success
- Potential dilution from future equity raises despite current cash position
- Historical calibration shows score-6 filings have only 56% observed up probability at T+20, though net alpha is positive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-PVLA-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | — |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | — |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | — |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | — |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | — |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | — |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | — |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access